Healthcare technology continues to evolve rapidly, prompting new discussions about how best to regulate these innovations. Mario, a health tech correspondent for STAT, covers the regulatory environment surrounding artificial intelligence in healthcare and how Medicare funds new technologies. His reporting also includes how AI is being used in clinical settings and the role of chatbots for mental health support. Additionally, he explores how consumer wearables are shaping personal health monitoring and tracking habits. STAT identifies Mario Aguilar as its health tech correspondent.
Mario is also the co-author of a twice-weekly newsletter focused on health technology trends, according to STAT News. The STAT Health Tech newsletter is distributed on Tuesdays and Thursdays.
The FDA has issued warnings to companies in the health tech space, highlighting safety and compliance issues, according to a report from STAT News. However, the recent warning letter discussed here involved pharmaceutical manufacturing rather than a digital health or health-tech company. The warning-letter story was reported by STAT's Ed Silverman.
One recent warning letter was posted on the FDA website last week. The letter pointed out several manufacturing problems at a facility, including residue and stains on production surfaces. Corrosion was also found in one of the product lines. The company was Shoolin Pharma Chem LLP, an active pharmaceutical ingredient manufacturer with a facility in Gujarat, India. FDA inspectors visited the drug manufacturing facility from April 13 through April 17, 2026.
An employee was observed wearing open-toed sandals during production, which raised concerns about safety standards. These issues were detailed in an August warning letter from the agency. The FDA said investigators also observed layered unidentified residues, improperly gowned employees and corroded equipment surfaces near open processing lines and API packaging.
The facility manufactures active pharmaceutical ingredients, including sildenafil citrate and tadalafil, that have been imported into the United States and used by compounding pharmacies. The FDA said the drugs were considered adulterated because they had been prepared, packed or held under insanitary conditions that could allow contamination.
The situation reflects broader concerns about how regulatory oversight keeps up with fast-moving tech industries. As digital health tools become more common, the FDA must balance innovation with public safety.
The agency's actions show it is actively monitoring manufacturing practices in the pharmaceutical industry. This includes reviewing how companies manage sanitation, equipment maintenance, laboratory records and quality-control procedures. In Shoolin's case, the FDA said the company lacked adequate procedures for cleaning and maintaining manufacturing equipment and could not provide evidence supporting some laboratory testing reported on certificates of analysis.
The warning letter highlights the importance of maintaining quality standards in health product development. Healthcare technology companies are under increasing scrutiny for meeting regulatory expectations.
The FDA’s role in ensuring that these tools are safe and effective is becoming more complex as the industry grows. With new technologies like AI and wearable devices entering clinical use, regulatory agencies must adapt their approaches. Aguilar's recent reporting has covered issues including Medicare payments for clinical AI, wearable data moving closer to clinical care and regulatory questions surrounding health chatbots.
The Shoolin case also resulted in stronger regulatory action. The FDA recommended on July 27 that the company recall all of its APIs then distributed in the United States, and Shoolin initiated a voluntary recall on August 4. The FDA also placed drugs from the facility on Import Alert 66-40 on August 11, allowing shipments to be detained or refused admission into the United States.
This shift in focus is part of a larger conversation about how to regulate digital health innovations responsibly. The evolving nature of these tools means that regulators must stay informed and responsive to new developments.
Healthcare professionals and technology developers alike are working to ensure that innovation does not compromise safety.